Fuda Cancer Hospital
Testicular cancer treatment cost in China typically includes a PET/CT scan that runs $300 to $600 and primary procedures like an orchiectomy, which ranges from $4,200 to $8,900. Total expenses depend on the cancer stage, the hospital tier, and whether advanced robotic techniques are used. Patients from Western countries often see 50-85% savings. Top treatment centers are located in Guangzhou, Beijing, and Shanghai.
Typical Testicular Cancer Treatment Costs in China
Bookimed Expert Insight: Late-stage patients find superior value at Joint Commission International (JCI) accredited centers like Fuda Cancer Hospital. This facility specializes in over 10 minimally invasive therapies beyond standard chemotherapy. For complex cases, choosing experts like Professor Liu Shi Xin at Xiamen Humanity Hospital is advisable. His leadership in radiation oncology ensures high-precision treatment protocols for international patients.
| China | Turkey | Austria | |
| Testicular prosthesis | from $3,800 | from $1,500 | from $3,500 |
| Removal of testicle tumor | from $7,200 | from $4,500 | from $8,500 |
| Radiation therapy for testicular cancer | from $8,500 | from $4,800 | from $6,955 |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Orchiectomy | from $4,200 | from $3,700 | from $9,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Written by Anna Leonova
Chinese hospitals identify testicular cancer types via pathology after a radical inguinal orchiectomy. Experts classify over 90% of cases as germ cell tumors. Staging follows international TNMS standards. This system evaluates the primary tumor, lymph nodes, distant metastasis, and serum tumor markers.
Bookimed Expert Insight: JCI-accredited centers like Fuda Cancer Hospital specialize in advanced cases where traditional chemotherapy might be replaced by minimally invasive therapies. Data shows these facilities often utilize NanoKnife and cryosurgery for complex presentations. Many patients choose these specialized centers in Guangzhou because they offer high-tech alternatives to standard protocols while maintaining international diagnostic accuracy.
Patient Consensus: Patients emphasize that a solid mass requires urgent evaluation since pain is often absent. They also note that normal blood markers do not always rule out malignancy.
Testicular cancer treatment in China typically preserves long-term testosterone production when one healthy testicle remains. Surgical removal of one testicle allows the other to compensate for hormone needs. Chemotherapy or radiation may temporarily suppress sperm production. Fertility preservation should be arranged before starting intensive clinical protocols.
Bookimed Expert Insight: While many focus on surgery, the primary long-term hormone risk comes from advanced chemotherapy regimens. At JCI-accredited centers like Fuda Cancer Hospital, doctors utilize minimally invasive therapies like cryosurgery. These targeted approaches can sometimes reduce the systemic impact compared to traditional heavy chemotherapy.
Patient Consensus: Patients emphasize that feeling normal doesn't guarantee fertility, as sperm counts often crash while testosterone remains steady. They recommend tracking LH and FSH levels for years after treatment to catch any delayed endocrine changes early.
International patients navigate language barriers and visa requirements through dedicated hospital international departments and structured medical invitation protocols. Specialized facilitators manage translation for registration and medical records. Official hospital invitations and proof of financial eligibility are essential for securing the necessary medical travel visas.
Bookimed Expert Insight: JCI-accredited centers like Fuda Cancer Hospital in Guangzhou serve over 30,000 international patients. This high volume often means administrative staff are more familiar with international paperwork. Choosing a facility with a dedicated international wing simplifies the initial registration process. This is where most communication friction typically occurs for new patients.
Patient Consensus: Patients emphasize that the biggest challenges occur during registration and bill payments rather than doctor consultations. They recommend keeping printed Chinese translations of your diagnosis and hospital address to assist with local transportation and staff check-in.
Traditional Chinese Medicine (TCM) safely integrates with Western protocols for testicular cancer through a supportive, non-ingestible approach. Acupuncture and mind-body exercises like Tai Chi effectively manage chemotherapy side effects. Ingestible herbs require strict oncological review to prevent liver toxicity or dangerous drug interactions.
Bookimed Expert Insight: Clinical data from JCI-accredited facilities like Fuda Cancer Hospital highlights a shift toward high-tech minimally invasive therapies. Clinics utilize microwave hyperthermia and cryosurgery alongside Western protocols instead of traditional herbal remedies. This focus on precision technology ensures treatments do not interfere with the 99% survival rate typical for early-stage testicular cancer.
Patient Consensus: Patients emphasize using Western oncology as the primary treatment backbone while viewing TCM solely for recovery and appetite. Most warn that natural does not mean safe and urge others to provide full ingredient lists to their doctors.